Diammonium glycyrrhizinate preparation for liver function recovery in chronic hepatitis B in China: a meta-analysis with trial sequential analysis
The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the plant extract diammonium glycyrrhizinate (DG) in food and medicine has gradually widened because of its safety and effectiveness. In clinical pra...
Saved in:
Published in | Current pharmaceutical design |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United Arab Emirates
01.01.2022
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the plant extract diammonium glycyrrhizinate (DG) in food and medicine has gradually widened because of its safety and effectiveness. In clinical practice, DG is mainly used for liver-disease treatment, but DG intervention for CHB lacks systematic-based evidence.
The included randomized controlled trials were analyzed by comparator and control respectively for alanine aminotransferase (ALT), aspartate transaminase (AST), and total bilirubin (TBIL) levels, hepatitis B virus DNA negative conversion ratio, and total effective rate, and subgroup analysis was conducted for intervention time, intervention dosage form, comparator drug, and combination drug, among others. Trial sequential analysis was used to verify the results.
DG could effectively reduce ALT, AST, TBIL, and other liver-function indexes and had a definite effect on liver-function recovery. From the beginning of intervention to 3 months, the effect was significantly better than that of conventional treatment. Compared with other drugs, different dosage forms had differences in efficacy, and DG enteric-coated capsules and injections were lower than compound glycyrrhizin and magnesium isoglycyrrhizin. Meanwhile DG capsules had no significant difference with them. Meanwhile, trial sequential analysis of the main results confirmed the reliability of the conclusion.
To our knowledge, this was the first relatively complete meta-analysis and systematic evaluation of the efficacy of DG intervention for CHB; liver-function recovery was discussed in the context of traditional Chinese medicine thinking, and DG's therapeutic effect in CHB was defined. |
---|---|
AbstractList | The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the plant extract diammonium glycyrrhizinate (DG) in food and medicine has gradually widened because of its safety and effectiveness. In clinical practice, DG is mainly used for liver-disease treatment, but DG intervention for CHB lacks systematic-based evidence.
The included randomized controlled trials were analyzed by comparator and control respectively for alanine aminotransferase (ALT), aspartate transaminase (AST), and total bilirubin (TBIL) levels, hepatitis B virus DNA negative conversion ratio, and total effective rate, and subgroup analysis was conducted for intervention time, intervention dosage form, comparator drug, and combination drug, among others. Trial sequential analysis was used to verify the results.
DG could effectively reduce ALT, AST, TBIL, and other liver-function indexes and had a definite effect on liver-function recovery. From the beginning of intervention to 3 months, the effect was significantly better than that of conventional treatment. Compared with other drugs, different dosage forms had differences in efficacy, and DG enteric-coated capsules and injections were lower than compound glycyrrhizin and magnesium isoglycyrrhizin. Meanwhile DG capsules had no significant difference with them. Meanwhile, trial sequential analysis of the main results confirmed the reliability of the conclusion.
To our knowledge, this was the first relatively complete meta-analysis and systematic evaluation of the efficacy of DG intervention for CHB; liver-function recovery was discussed in the context of traditional Chinese medicine thinking, and DG's therapeutic effect in CHB was defined. |
Author | Li, Minhui Liu, Yibo Guo, Wenfang |
Author_xml | – sequence: 1 givenname: Yibo surname: Liu fullname: Liu, Yibo organization: Institute Mongolia Medical University, Hohhot , China – sequence: 2 givenname: Wenfang surname: Guo fullname: Guo, Wenfang organization: Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot , China – sequence: 3 givenname: Minhui surname: Li fullname: Li, Minhui organization: Baotou Medical College, Baotou , China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35593360$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kEtOwzAURS0Eoh_YAjILCPgbO8yg5SdVYgLjykleiFHiBMcBhWWwYlygo3d1j94Z3AU6dJ0DhM4puWBUiUvKNU0p00ynacoYEYxSLjJKDtCcasUTEckMLYbhjRDKMiqO0YxLmXGekjn6XlvTtp2zY4tfm6mYvK_tl3UmAO499MabYDuHq87jxn6Ax9Xoit_KQ9HFYsLW4aL20VHgOn4EG-yAb3b1qo6mK2xwC8EkxplmGiL7tKHGwVvT4AHeR3BhF_f4BB1Vphng9P8u0cvd7fPqIdk83T-urjdJLjQLiRayjAPkxigigWkACrnWPFdQplVWlEYoVVW8klBmquQxSkoMJ7JUBcklW6KzP28_5i2U297b1vhpux-H_QA_DW0b |
CitedBy_id | crossref_primary_10_1016_j_phymed_2023_154883 crossref_primary_10_1016_j_toxicon_2024_107795 crossref_primary_10_1097_SHK_0000000000002353 crossref_primary_10_1016_j_intimp_2024_113374 |
ContentType | Journal Article |
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
Copyright_xml | – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
DBID | NPM |
DOI | 10.2174/1381612828666220421134910 |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-4286 |
ExternalDocumentID | 35593360 |
Genre | Meta-Analysis |
GroupedDBID | --- .5. 0R~ 29F 36B 4.4 53G 5GY AAEGP ABEEF ABJNI ABVDF ACGFO ACGFS ACITR ACIWK ACPRK ACZAY AENEX AFRAH AFUQM AGJNZ AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS ANTIV CS3 DU5 EBS F5P GH2 HZ~ IPNFZ KCGFV KFI NPM O9- P2P RIG |
ID | FETCH-LOGICAL-b482t-845d174baa705e28ee1eb883b7ed6f9cda477ff3f5ed97d3ff3510a305d7c0b52 |
IngestDate | Thu Jan 02 22:56:28 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | chronic hepatitis B meta-analysis ALT TSA diammonium glycyrrhizinate TCM |
Language | English |
License | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-b482t-845d174baa705e28ee1eb883b7ed6f9cda477ff3f5ed97d3ff3510a305d7c0b52 |
PMID | 35593360 |
ParticipantIDs | pubmed_primary_35593360 |
PublicationCentury | 2000 |
PublicationDate | 2022-01-01 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United Arab Emirates |
PublicationPlace_xml | – name: United Arab Emirates |
PublicationTitle | Current pharmaceutical design |
PublicationTitleAlternate | Curr Pharm Des |
PublicationYear | 2022 |
SSID | ssj0012914 |
Score | 2.3992758 |
SecondaryResourceType | review_article |
Snippet | The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the... |
SourceID | pubmed |
SourceType | Index Database |
Title | Diammonium glycyrrhizinate preparation for liver function recovery in chronic hepatitis B in China: a meta-analysis with trial sequential analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35593360 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBabFkIupen7kTKFksvGrVeWLbu3JG0JpS05bGhuQbKkrCDrLIn3sKG_or-4I8lee5cG0l6MmVm8RvOheXjmEyHvDGOKZlpFXMsyYrlQUZGURcSoiI02yqSJG07-_iM7OmFfT9PTweBXf7qklu_Lm7_OlfyPVVGGdnVTsv9g2eVDUYD3aF-8ooXxeicbf7LC_ZmdT4fnF4tycXU1sTe2wvDRzf4HVu-mk_DC9V8MnRfzIpcHo8AP_ZWBHxdjRtddXdvr4YGfBXQna4dZ6KmuRSRa-pJQuvWnfYRG7Np6woGg7ke7LfnTbLJSOFcrXSPf7Nz7ASsvl81Ac1_A_akrIxrP6n8Y-vyrydz2ixWU9ooVOmywOU8QCIH-en37dumRqyS4j5kjlwtibkUpbisjR6IY2l97Zp1NvV0xYiqSJLuDdo1Zu1VtkA3MMdyhqa7S03yBosWIbZK3zVt9uPWdtshm-5y1zMRHKOOH5EGTWsB-wMk2GejqEdk9Dmu_2INxN2p3vQe7cNyxli8ek98dmGANTNADEyCYwIMJWjBBCyawFTRggiWY4MCJPZg-goAVKIGDEngoQQclaNVPyMmXz-PDo6g5sCOSLKd1lLNU4WJJIXicapprPdIyzxPJtcpMUSrBODcmMalWBVcJ3qJLEOhyFC9jmdKn5F51WennBFiWF2XKTZwKyZSJJS8TnaVaZrGmSscvyLOw1mezwMpy1lrh5a2aV2Srw-Rrct_gNqB3MKas5Rtv_D_Gn32D |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diammonium+glycyrrhizinate+preparation+for+liver+function+recovery+in+chronic+hepatitis+B+in+China%3A+a+meta-analysis+with+trial+sequential+analysis&rft.jtitle=Current+pharmaceutical+design&rft.au=Liu%2C+Yibo&rft.au=Guo%2C+Wenfang&rft.au=Li%2C+Minhui&rft.date=2022-01-01&rft.eissn=1873-4286&rft_id=info:doi/10.2174%2F1381612828666220421134910&rft_id=info%3Apmid%2F35593360&rft_id=info%3Apmid%2F35593360&rft.externalDocID=35593360 |